<sup>99m</sup>Tc-MAG3-Aptamer for Imaging Human Tumors Associated with High Level of Matrix Metalloprotease-9

Gomes, Sonia Da Rocha; Miguel, Julie; Azéma, Laurent; Eimer, Sandrine; Ries, Colette; Dausse, Eric; Loiseau, Hugues; Allard, Michèle; Toulmé, Jean‐Jacques

doi:10.1021/bc300146c

Cited by 40 publications

(27 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, two aptamers demonstrated significantly higher tumor uptake than a control oligonucleotide: a DNA aptamer selected against epidermal growth factor receptor variant III (EGFRvIII) [32] and a fully modified aptamer (2'Ome-Purine/2'F-Py) that binds to matrix metalloprotease-9 (MMP9) [33,34]. The latter was radiolabeled either with 99m Tc-MAG or 111 In-DOTA [34].…”

Section: Single Photon Emission Computed Tomography (Spect)mentioning

confidence: 99%

Application of aptamers for in vivo molecular imaging and theranostics

Bouvier-Müller

Ducongé

2018

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Nucleic acid aptamers are small three-dimensional structures of oligonucleotides selected to bind to a target of interest with high affinity and specificity. In vitro, aptamers already compete with antibodies to serve as imaging probes, e.g. for microscopy or flow cytometry. However, they are also increasingly used for in vivo molecular imaging. Accordingly, aptamers have been evaluated over the last twenty years in almost every imaging modality, including single photon emission computed tomography, positron emission tomography, magnetic resonance imaging, fluorescence imaging, echography, and x-ray computed tomography. This review focuses on the studies that were conducted in vivo with aptamer-based imaging probes. It also presents how aptamers have been recently used to develop new types of probes for multimodal imaging and theranostic applications.

show abstract

Section: Single Photon Emission Computed Tomography (Spect)mentioning

confidence: 99%

Application of aptamers for in vivo molecular imaging and theranostics

Bouvier-Müller

Ducongé

2018

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…TTA1's utility was found not to be limited only to glioblastoma cells; the expression of tenascin-C in breast, colon, lung, lymphoma, melanoma, prostate, and sarcoma carcinomas allows for the diverse application of the TTA1 aptamer imaging [15]. Another aptamer-based nanoprobe utilized an RNA aptamer for human matrix metalloprotease 9 (hMMP-9) a protein that, when over-expressed, contributes to tumor metastasis [126]. A radiolabelled, S-acetylmercaptroacetyltriglycine (MAG3)-conjugated aptamer probe ( 99m Tc-MAG3-aptamer) was developed to specifically detect hMMP-9 in eight different brain tumor types using ex vivo brain slices.…”

Section: Targets Related To Brain Cancer (Glioblastoma and Glioma)mentioning

confidence: 99%

Aptamers as Promising Molecular Recognition Elements for Diagnostics and Therapeutics in the Central Nervous System

McConnell

Holahan

DeRosa

2014

Nucleic Acid Therapeutics

View full text Add to dashboard Cite

Oligonucleotide aptamers are short, synthetic, single-stranded DNA or RNA able to recognize and bind to a multitude of targets ranging from small molecules to cells. Aptamers have emerged as valuable tools for fundamental research, clinical diagnosis, and therapy. Due to their small size, strong target affinity, lack of immunogenicity, and ease of chemical modification, aptamers are an attractive alternative to other molecular recognition elements, such as antibodies. Although it is a challenging environment, the central nervous system and related molecular targets present an exciting potential area for aptamer research. Aptamers hold promise for targeted drug delivery, diagnostics, and therapeutics. Here we review recent advances in aptamer research for neurotransmitter and neurotoxin targets, demyelinating disease and spinal cord injury, cerebrovascular disorders, pathologies related to protein aggregation (Alzheimer's, Parkinson's, and prions), brain cancer (glioblastomas and gliomas), and regulation of receptor function. Challenges and limitations posed by the blood brain barrier are described. Future perspectives for the application of aptamers to the central nervous system are also discussed.

show abstract

“…The binding characteristics of aptamers, namely high affinity and specific recognition of the target as well as their easy of synthesis made them excellent candidates for imaging. Aptamer-based probes have been engineered for monitoring several tumor markers: nucleolin [ 27 ], tenascin [ 28 ], PSMA [ 29 ], PTK7 or MUC1 glycoprotein [ 30 – 31 ], annexin A2 [ 32 ] or MMP-9 [ 33 ]. The versatility of oligonucleotide synthesis allows the chemical modifications od aptamers at defined positions without effect on their binding properties.…”

Section: Introductionmentioning

confidence: 99%

Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas

et al. 2016

Self Cite

View full text Add to dashboard Cite

The human Matrix MetalloProtease-9 (hMMP-9) is overexpressed in tumors where it promotes the release of cancer cells thus contributing to tumor metastasis. We raised aptamers against hMMP-9, which constitutes a validated marker of malignant tumors, in order to design probes for imaging tumors in human beings. A chemically modified RNA aptamer (F3B), fully resistant to nucleases was previously described. This compound was subsequently used for the preparation of F3B-Cy5, F3B-S-acetylmercaptoacetyltriglycine (MAG) and F3B-DOTA. The binding properties of these derivatives were determined by surface plasmon resonance and electrophoretic mobility shift assay. Optical fluorescence imaging confirmed the binding to hMMP-9 in A375 melanoma bearing mice. Quantitative biodistribution studies were performed at 30 min, 1h and 2 h post injection of 99mTc-MAG-aptamer and 111In-DOTA-F3B. 99mTc radiolabeled aptamer specifically detected hMMP-9 in A375 melanoma tumors but accumulation in digestive tract was very high. Following i.v. injection of 111In-DOTA-F3B, high level of radioactivity was observed in kidneys and bladder but digestive tract uptake was very limited. Tumor uptake was significantly (student t test, p<0.05) higher for 111In-DOTA-F3B with 2.0%ID/g than for the 111In-DOTA-control oligonucleotide (0.7%ID/g) with tumor to muscle ratio of 4.0. Such difference in tumor accumulation has been confirmed by ex vivo scintigraphic images performed at 1h post injection and by autoradiography, which revealed the overexpression of hMMP-9 in sections of human melanomas. These results demonstrate that F3B aptamer is of interest for detecting hMMP-9 in melanoma tumor.

show abstract

^99mTc-MAG3-Aptamer for Imaging Human Tumors Associated with High Level of Matrix Metalloprotease-9

Cited by 40 publications

References 52 publications

Application of aptamers for in vivo molecular imaging and theranostics

Application of aptamers for in vivo molecular imaging and theranostics

Aptamers as Promising Molecular Recognition Elements for Diagnostics and Therapeutics in the Central Nervous System

Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas

Contact Info

Product

Resources

About